Request Deal Involvement

Gurnet Point Capital and Novo completed the acquisition of Paratek Pharmaceuticals for $462m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

Lazard

financial advisors

Lazard

Sullivan & Cromwell

legal advisors to debt providers

Sullivan & Cromwell

Oaktree Capital Management

debt providers

Oaktree Capital Management

H/Advisors Abernathy

pr advisors

H/Advisors Abernathy

FGS Global

pr advisors

FGS Global

Moelis & Co

financial advisors

Moelis & Co

Ropes & Gray

legal advisors

Ropes & Gray

Freshfields Bruckhaus Deringer

legal advisors to financial advisors

Freshfields Bruckhaus Deringer

Goodwin Procter

legal advisors

Goodwin Procter

or

Principals

GURNET POINT CAPITAL LIMITED

bidder

GURNET POINT CAPITAL LIMITED

PARATEK PHARMACEUTICALS

target

PARATEK PHARMACEUTICALS

NOVO HOLDINGS A/S

bidder

NOVO HOLDINGS A/S

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Gurnet Point Capital and Novo completed the acquisition of Paratek Pharmaceuticals for $462m.